前列腺癌罕见组织学亚型:检测、特征与治疗综述
Rare prostate cancer histologies: detection, characteristics and treatment
该综述系统总结了前列腺癌罕见组织学亚型的病理检出难点、分子特征与当前治疗证据。文章覆盖神经内分泌型、腺泡癌伴导管成分、黏液腺癌、基底细胞癌及小细胞癌等亚型,并结合指南、影像与基因组学进展讨论了诊疗策略。
Bronkema, C. et al. Rare histological variants of prostate adenocarcinoma: a National Cancer Database Analysis. J. Urol. 204, 260–266 https://doi.org/10.1097/JU.0000000000001011 (2020).
Zhou, J., Ding, J. & Qi, J. Comparison of typical prostate adenocarcinoma and rare histological variant prostate cancer showed different characteristics and prognosis: a surveillance, epidemiology, and end results database analysis. Eur. Urol. 82, 152–155 https://doi.org/10.1016/j.eururo.2022.02.006 (2022).
Kench, J. G. et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 81, 447–458 https://doi.org/10.1111/his.14711 (2022).
Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 https://doi.org/10.3322/caac.21388 (2017).
Jetty, S. et al. Prostate cancer — PET imaging update. Cancers 15, 796 https://doi.org/10.3390/cancers15030796 (2023).
Spratt, D. E., Srinivas, S., Adra, N. et al. NCCN Guidelines Version 7.2026 Prostate Cancer, https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2026).
Mohanty, S. K., Lobo, A. & Cheng, L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum. Pathol. 136, 123–143 https://doi.org/10.1016/j.humpath.2022.08.006 (2023).
Epstein, J. I. & Lieberman, P. H. Mucinous adenocarcinoma of the prostate gland. Am. J. Surg. Pathol. 9, 299–308 https://doi.org/10.1097/00000478-198504000-00006 (1985).
Riddle, N. et al. Recent advances in genitourinary tumors: updates from the 5th edition of the World Health Organization Blue Book Series. Arch. Pathol. Lab. Med. 148, 952–964 https://doi.org/10.5858/arpa.2022-0509-RA (2024).
Siech, C. et al. Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-024-00866-4 (2024).
Jaratlerdsiri, W. et al. African-specific molecular taxonomy of prostate cancer. Nature 609, 552–559 https://doi.org/10.1038/s41586-022-05154-6 (2022).
Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 129, 4492–4505 https://doi.org/10.1172/JCI128212 (2019).
Cozzi, S. et al. Adenoid cystic carcinoma/basal cell carcinoma of the prostate: overview and update on rare prostate cancer subtypes. Curr. Oncol. 29, 1866–1876 https://doi.org/10.3390/curroncol29030152 (2022).
Spetsieris, N., Boukovala, M., Patsakis, G., Alafis, I. & Efstathiou, E. Neuroendocrine and aggressive-variant prostate cancer. Cancers 12, 3792 https://doi.org/10.3390/cancers12123792 (2020).
Paner, G. P., Gandhi, J., Choy, B. & Amin, M. B. Essential updates in grading, morphotyping, reporting, and staging of prostate carcinoma for general surgical pathologists. Arch. Pathol. Lab. Med. 143, 550–564 https://doi.org/10.5858/arpa.2018-0334-RA (2019).
Hambrock, T. et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259, 453–461 https://doi.org/10.1148/radiol.11091409 (2011).
Hötker, A. M. et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI. AJR Am. J. Roentgenol. 206, 756–763 https://doi.org/10.2214/AJR.15.14912 (2016).
van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 44, e87–e99 https://doi.org/10.1097/PAS.0000000000001497 (2020).
Netto, G. J. et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur. Urol. 82, 469–482 https://doi.org/10.1016/j.eururo.2022.07.002 (2022).
Carneiro, A. et al. The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: a systematic review of the literature. Front. Oncol. 8, 377 https://doi.org/10.3389/fonc.2018.00377 (2018).
Fine, S. W. Evolution in prostate cancer staging: pathology updates from AJCC 8th edition and opportunities that remain. Adv. Anat. Pathol. 25, 327–332 https://doi.org/10.1097/PAP.0000000000000200 (2018).
Abida, W., Beltran, H. & Raychaudhuri, R. State of the art: personalizing treatment for patients with metastatic castration-resistant prostate cancer. Am. Soc. Clin. Oncol. Educ. Book 45, e473636 https://doi.org/10.1200/EDBK-25-473636 (2025).
Dawson, N. A. et al. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer. Mol. Cancer Ther. 19, 1373–1382 https://doi.org/10.1158/1535-7163.MCT-19-0531 (2020).
Yu, E. Y. et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J. Clin. Oncol. 43, 748–758 https://doi.org/10.1200/JCO-24-02608 (2025).
Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 https://doi.org/10.1038/nm.4045 (2016).
NCCN. NCCN Clinical Practice Guidelines on Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf version 1 (2025).
Böttcher, R. et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 18, 8 https://doi.org/10.1186/s12885-017-3976-z (2018).
Risbridger, G. P. et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496–503 https://doi.org/10.1016/j.eururo.2014.08.007 (2015).
Galloway, G. L., Malmberg, R. L. & Price, R. A. Phylogenetic utility of the nuclear gene arginine decarboxylase: an example from Brassicaceae. Mol. Biol. Evol. 15, 1312–1320 https://doi.org/10.1093/oxfordjournals.molbev.a025859 (1998).
Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 https://doi.org/10.1056/NEJMoa1603144 (2016).
Lotan, T. L. et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24, 820–828 https://doi.org/10.1038/modpathol.2011.7 (2011).
Alhamar, M. et al. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology 77, 890–899 https://doi.org/10.1111/his.14205 (2020).
Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 https://doi.org/10.1200/JCO.2017.77.6880 (2018).
Aparicio, A. M. et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin. Cancer Res. 22, 1520–1530 https://doi.org/10.1158/1078-0432.CCR-15-1259 (2016).
Weiss, S. et al. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies. Int. J. Cancer 155, 298–313 https://doi.org/10.1002/ijc.34949 (2024).
Schweizer, M. T. et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7, 82504–82510 https://doi.org/10.18632/oncotarget.12697 (2016).
Zhu, Q. et al. Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma. J. Pathol. Clin. Res. 11, e70026 https://doi.org/10.1002/2056-4538.70026 (2025).
Schweizer, M. T. et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00327 (2019).
Inamura, K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget 9, 14723–14737 https://doi.org/10.18632/oncotarget.24515 (2018).
Cheng, H. H. et al. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis. Oncol. 7, e2200104 https://doi.org/10.1200/PO.22.00104 (2023).
Bulten, W. et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 21, 233–241 https://doi.org/10.1016/S1470-2045(19)30739-9 (2020).
Sklinda, K. et al. Radiomics-based characterization of aggressive prostate cancer variants: diagnostic challenges and opportunities. Cancers 18, 780 https://doi.org/10.3390/cancers18050780 (2026).
Ni, H. M. et al. The state of the art in artificial intelligence and digital pathology in prostate cancer. Nat. Rev. Urol. 23, 13–28 https://doi.org/10.1038/s41585-025-01070-2 (2026).
Medina, S. et al. A computational pathology model to predict docetaxel benefit in localized high-risk and metastatic prostate cancer. Clin. Cancer Res. 32, 645–653 https://doi.org/10.1158/1078-0432.CCR-25-3327 (2026).
Ramesh, N. et al. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol. 21, 162 https://doi.org/10.1186/s13059-020-02045-9 (2020).
Del Re, M. et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol. 71, 680–687 https://doi.org/10.1016/j.eururo.2016.08.012 (2017).
McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882–889 https://doi.org/10.1001/jamaoncol.2016.0097 (2016).
Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578–583 https://doi.org/10.1053/hp.2000.6698 (2000).
Ullah, A. et al. Clinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S. An analysis of SEER database. Can. Urol. Assoc. J. 18, E334–E338 https://doi.org/10.5489/cuaj.8769 (2024).
Ranasinha, N. et al. Ductal adenocarcinoma of the prostate: a systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass 2, 13–23 https://doi.org/10.1002/bco2.60 (2021).
Fonteyne, V., Tree, A., Castro, E., Touijer, K. & Walz, J. Prostate cancer. Lancet 407, 622–636 https://doi.org/10.1016/S0140-6736(25)02221-4 (2026).
Lundberg, A. et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 83, 2763–2774 https://doi.org/10.1158/0008-5472.CAN-23-0593 (2023).
Haffner, M. C. et al. Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies. Clin. Cancer Res. 31, 466–478 https://doi.org/10.1158/1078-0432.CCR-24-2061 (2025).
Zhao, T. et al. Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. Hum. Pathol. 128, 101–109 https://doi.org/10.1016/j.humpath.2022.07.018 (2022).
Karsiyakali, N. et al. The prostatic adenocarcinoma with mucinous features: a review of the literature with three case reports. J. Cancer Res. Ther. 17, 596–598 https://doi.org/10.4103/jcrt.JCRT_673_18 (2021).
Samaratunga, H. et al. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 71, 641–647 https://doi.org/10.1111/his.13278 (2017).
Zhao, F. et al. Mucinous prostate cancer shows similar prognosis to typical prostate acinar carcinoma: a large population-based and propensity score-matched study. Front. Oncol. 9, 1467 https://doi.org/10.3389/fonc.2019.01467 (2019).
Bong, J. W. et al. Prognosis and sensitivity of adjuvant chemotherapy in mucinous colorectal adenocarcinoma without distant metastasis. Cancers 14, 1297 https://doi.org/10.3390/cancers14051297 (2022).
Osunkoya, A. O. Mucinous and secondary tumors of the prostate. Mod. Pathol. 31, S80–S95 https://doi.org/10.1038/modpathol.2017.132 (2018).
Yamada, K., Kozawa, N., Nagano, H. & Fujita, M. MRI features of mucinous adenocarcinoma of the prostate: report of four cases. Abdom. Radiol. 44, 1261–1268 https://doi.org/10.1007/s00261-019-01956-x (2019).
Sun, Z., Jiang, X., Fu, G., Sun, S. & Tao, W. The characteristics of prostate mucinous adenocarcinoma visualized by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET/CT. Clin. Nucl. Med. 50, 743–745 https://doi.org/10.1097/RLU.0000000000006004 (2025).
Osunkoya, A. O., Nielsen, M. E. & Epstein, J. I. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am. J. Surg. Pathol. 32, 468–472 https://doi.org/10.1097/PAS.0b013e3181589f72 (2008).
Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 https://doi.org/10.1097/PAS.0000000000000530 (2016).
Zhang, Y. et al. Case report: prostate adenocarcinoma with mucinous features of normal-level serum PSA, atypical imaging, biopsy-negative, and peculiar urethrocystoscopic manifestation. Front. Oncol. 10, 504381 https://doi.org/10.3389/fonc.2020.504381 (2020).
Montatore, M., Eusebi, L., Masino, F., Balbino, M. & Guglielmi, G. Mucinous adenocarcinoma of the prostate: a rare tumor - case report and literature review. J. Ultrason. 25, 20250027 https://doi.org/10.15557/jou.2025.0027 (2025).
Siech, C. et al. Cancer-specific mortality in rare histological subtypes of prostate cancer: radical prostatectomy versus radiation therapy. Ann. Surg. Oncol. 33, 5865–5873 https://doi.org/10.1245/s10434-026-19245-5 (2026).
Teichman, J. M., Shabaik, A. & Demby, A. M. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J. Urol. 151, 701–702 https://doi.org/10.1016/s0022-5347(17)35054-1 (1994).
Warner, J. N., Nakamura, L. Y., Pacelli, A., Humphreys, M. R. & Castle, E. P. Primary signet ring cell carcinoma of the prostate. Mayo Clin. Proc. 85, 1130–1136 https://doi.org/10.4065/mcp.2010.0463 (2010).
Lane, B. R. et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 68, 825–830 https://doi.org/10.1016/j.urology.2006.04.028 (2006).
Humphrey, P. A. Histopathology of prostate cancer. Cold Spring Harb. Perspect. Med. 7, a030411 https://doi.org/10.1101/cshperspect.a030411 (2017).
Zong, Y. et al. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. Eur. Urol. Focus. 7, 955–963 https://doi.org/10.1016/j.euf.2020.10.007 (2021).
Shah, R. B., Varma, M., Zhou, M., Paner, G. P. & Kristiansen, G. Diagnosis and reporting of intraductal carcinoma of the prostate: a guide for practising pathologists with excerpts from the Genitourinary Pathology Society and the International Society of Urological Pathology Joint Expert Consultation. Adv. Anat. Pathol. 33, 331–341 https://doi.org/10.1097/PAP.0000000000000547 (2026).
Porter, L. H. et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur. Urol. 72, 492–495 https://doi.org/10.1016/j.eururo.2017.03.013 (2017).
Kang, M., Lee, H., Byeon, S. J., Kwon, G. Y. & Jeon, S. S. Genomic features and clinical implications of intraductal carcinoma of the prostate. Int. J. Mol. Sci. 22, 13125 https://doi.org/10.3390/ijms222313125 (2021).
Divatia, M. K. & Ro, J. Y. Intraductal carcinoma of the prostate gland: recent advances. Yonsei Med. J. 57, 1054–1062 https://doi.org/10.3349/ymj.2016.57.5.1054 (2016).
Grypari, I. M., Pomoni, A. & Tzelepi, V. Intraductal carcinoma of the prostate: a comprehensive literature review focused on grading challenges and controversies. Histol. Histopathol. 40, 1869–1888 https://doi.org/10.14670/HH-18-939 (2025).
Diop, M. K. et al. Identification of morphologic criteria associated with biochemical recurrence in intraductal carcinoma of the prostate. Cancers 13, 6243 https://doi.org/10.3390/cancers13246243 (2021).
Wasinger, G., Oszwald, A., Shariat, S. F. & Compérat, E. Histological patterns, subtypes and aspects of prostate cancer: different aspects, different outcomes. Curr. Opin. Urol. 32, 643–648 https://doi.org/10.1097/MOU.0000000000001038 (2022).
Cao, F. et al. Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer. BMC Urol. 25, 10 https://doi.org/10.1186/s12894-025-01690-1 (2025).
Han, C. et al. Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information. Insights Imaging 12, 79 https://doi.org/10.1186/s13244-021-01024-3 (2021).
Miyai, K. et al. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum. Pathol. 45, 1572–1581 https://doi.org/10.1016/j.humpath.2014.03.011 (2014).
Ranasinghe, W. et al. Optimizing the diagnosis and management of ductal prostate cancer. Nat. Rev. Urol. 18, 337–358 https://doi.org/10.1038/s41585-021-00447-3 (2021).
Wobker, S. E. & Epstein, J. I. Differential diagnosis of intraductal lesions of the prostate. Am. J. Surg. Pathol. 40, e67–e82 https://doi.org/10.1097/PAS.0000000000000609 (2016).
Zhu, S., Xu, N. & Zeng, H. Molecular complexity of intraductal carcinoma of the prostate. Cancer Med. 13, e6939 https://doi.org/10.1002/cam4.6939 (2024).
Bernhardt, M. & Kristiansen, G. Molecular alterations in intraductal carcinoma of the prostate. Cancers 15, 5512 https://doi.org/10.3390/cancers15235512 (2023).
Cui, Y. et al. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate. J. Cancer Res. Clin. Oncol. 150, 45 https://doi.org/10.1007/s00432-023-05582-5 (2024).
Taylor, R. A. et al. The influence of BRCA2 mutation on localized prostate cancer. Nat. Rev. Urol. 16, 281–290 https://doi.org/10.1038/s41585-019-0164-8 (2019).
Zhao, J. et al. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget 8, 55374–55383 https://doi.org/10.18632/oncotarget.19520 (2017).
Naito, Y. et al. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer. Prostate 83, 307–315 https://doi.org/10.1002/pros.24462 (2023).
Ditonno, F. et al. Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: a systematic review and meta-analysis using contemporary consensus recommendations. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-026-01143-2 (2026).
Aizawa, R. et al. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Sci. 113, 2425–2433 https://doi.org/10.1111/cas.15392 (2022).
Miyajima, K. et al. Clinical significance of intraductal carcinoma of the prostate after high-dose brachytherapy with external beam radiation therapy: a single institution series and an updated meta-analysis. Clin. Genitourin. Cancer 22, 149–156.e1 https://doi.org/10.1016/j.clgc.2023.10.005 (2024).
Shi, Y. et al. Ductal, intraductal, and cribriform carcinoma of the prostate: molecular characteristics and clinical management. Urol. Oncol. 42, 144–154 https://doi.org/10.1016/j.urolonc.2024.01.037 (2024).
Knipper, S. et al. Contemporary comparison of clinicopathologic characteristics and survival outcomes of prostate ductal carcinoma and acinar adenocarcinoma: a population-based study. Clin. Genitourin. Cancer 17, 231–237.e2 https://doi.org/10.1016/j.clgc.2019.04.009 (2019).
Sha, J. et al. Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance. Onco Targets Ther. 6, 1501–1506 https://doi.org/10.2147/OTT.S47165 (2013).
Morgan, T. M., Welty, C. J., Vakar-Lopez, F., Lin, D. W. & Wright, J. L. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J. Urol. 184, 2303–2307 https://doi.org/10.1016/j.juro.2010.08.017 (2010).
Edo, H. et al. Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series. Abdom. Radiol. 47, 1929–1938 https://doi.org/10.1007/s00261-022-03454-z (2022).
Ranasinghe, W. K. B. et al. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126, 3667–3673 https://doi.org/10.1002/cncr.32957 (2020).
Wei, Y. et al. Comparison of survival outcomes and risk factors between ductal carcinoma of the prostate and acinar adenocarcinoma of the prostate: a population-based propensity score-matching study. Eur. Urol. Open Sci. 46, 88–95 https://doi.org/10.1016/j.euros.2022.10.013 (2022).
Cozzi, S. et al. Ductal prostate cancer: clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature. Curr. Urol. 16, 218–226 https://doi.org/10.1097/CU9.0000000000000118 (2022).
Lindh, C. et al. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate 82, 576–583 https://doi.org/10.1002/pros.24304 (2022).
Lenis, A. T. et al. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin. Cancer Res. 30, 3894–3903 https://doi.org/10.1158/1078-0432.CCR-23-3403 (2024).
McNevin, C. S. et al. Prevalence of mismatch repair deficiency in primary prostate cancer in a large prospective cohort. Clin. Cancer Res. 31, 1746–1753 https://doi.org/10.1158/1078-0432.CCR-24-1210 (2025).
Kurokawa, K. et al. Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy. Sci. Rep. 14, 14868 https://doi.org/10.1038/s41598-024-65681-2 (2024).
Ranasinghe, W. et al. Ductal prostate cancers demonstrate poor outcomes with conventional therapies. Eur. Urol. 79, 298–306 https://doi.org/10.1016/j.eururo.2020.11.015 (2021).
Bronkema, C. et al. Impact of treatment modality on overall survival in localized ductal prostate adenocarcinoma: a National Cancer Database analysis. Urol. Oncol. 39, 366.e11–366.e18 https://doi.org/10.1016/j.urolonc.2020.11.013 (2021).
Shi, Y. et al. The prognostic value of the prostate adenocarcinoma with ductal feature in patients with advanced prostate cancer treated with abiraterone acetate. Prostate 85, 659–669 https://doi.org/10.1002/pros.24869 (2025).
Chow, K. et al. Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. Eur. J. Cancer 148, 440–450 https://doi.org/10.1016/j.ejca.2020.12.030 (2021).
Azad, A. A. et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267–1276 https://doi.org/10.1016/S1470-2045(24)00440-6 (2024).
Tsai, H. K. et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer 17, 759 https://doi.org/10.1186/s12885-017-3729-z (2017).
Heimdörfer, D., Artamonova, N., Culig, Z. & Heidegger, I. Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer. J. Cancer Res. Clin. Oncol. 150, 462 https://doi.org/10.1007/s00432-024-05983-0 (2024).
Chen, J. et al. Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis. BJUI Compass 4, 256–265 https://doi.org/10.1002/bco2.212 (2023).
Taher, A. et al. Imaging of neuroendocrine prostatic carcinoma. Cancers 13, 5765 https://doi.org/10.3390/cancers13225765 (2021).
Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann. Oncol. 31, 470–479 https://doi.org/10.1016/j.annonc.2020.02.002 (2020).
Zamora, I., Freeman, M. R., Encío, I. J. & Rotinen, M. Targeting key players of neuroendocrine differentiation in prostate cancer. Int. J. Mol. Sci. 24, 13673 https://doi.org/10.3390/ijms241813673 (2023).
Christenson, M., Song, C. S., Liu, Y. G. & Chatterjee, B. Precision targets for intercepting the lethal progression of prostate cancer: potential avenues for personalized therapy. Cancers 14, 892 https://doi.org/10.3390/cancers14040892 (2022).
Nguyen, N. et al. A systematic review of primary large cell neuroendocrine carcinoma of the prostate. Front. Oncol. 14, 1341794 https://doi.org/10.3389/fonc.2024.1341794 (2024).
Yamada, Y. & Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 23, 15 https://doi.org/10.1007/s11912-020-01003-9 (2021).
Brady, N. J. et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat. Commun. 12, 3372 https://doi.org/10.1038/s41467-021-23780-y (2021).
Trabulsi, E. J. et al. Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J. Clin. Oncol. 38, 1963–1996 https://doi.org/10.1200/JCO.19.02757 (2020).
Yao, J. et al. Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study. Front. Endocrinol. 12, 778758 https://doi.org/10.3389/fendo.2021.778758 (2021).
de Kouchkovsky, I., Chan, E., Schloss, C., Poehlein, C. & Aggarwal, R. Diagnosis and management of neuroendocrine prostate cancer. Prostate 84, 426–440 https://doi.org/10.1002/pros.24664 (2024).
Wang, Y., Ci, X., Choi, S. Y. C., Crea, F. & Lin, D. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581–596 https://doi.org/10.1038/s41585-021-00490-0 (2021).
Ploussard, G. et al. Chromogranin A: a useful biomarker in castration-resistant prostate cancer. World J. Urol. 41, 361–369 https://doi.org/10.1007/s00345-022-04248-0 (2023).
Kaur, H. et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: molecular characterization and clinical significance. Prostate 80, 1012–1023 https://doi.org/10.1002/pros.24035 (2020).
Serritella, A. V. et al. Large cell neuroendocrine prostate cancer: large is not small. Oncologist 29, 185–189 https://doi.org/10.1093/oncolo/oyad344 (2024).
Karzai, F. & Madan, R. A. Deciphering the enigma of neuroendocrine prostate cancer. J. Clin. Invest. 132, e164611 https://doi.org/10.1172/JCI164611 (2022).
Brady, L. & Nelson, P. S. RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer. J. Endocrinol. 256, e220211 https://doi.org/10.1530/JOE-22-0211 (2023).
Singh, R. et al. Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity. Nat. Commun. 17, 2992 https://doi.org/10.1038/s41467-026-69308-0 (2026).
Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat. Commun. 12, 1979 https://doi.org/10.1038/s41467-021-22139-7 (2021).
Beltran, H. & Demichelis, F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr. Relat. Cancer 28, T67–T78 https://doi.org/10.1530/ERC-21-0140 (2021).
Chau, V. et al. Anaplastic features in advanced prostate cancer with and without DNA damage repair mutations. Clin. Genitourin. Cancer 19, e352–e359 https://doi.org/10.1016/j.clgc.2021.05.005 (2021).
Moore, S. R., Reinberg, Y. & Zhang, G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 39, 411–416 https://doi.org/10.1016/0090-4295(92)90235-o (1992).
Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I. & Eisenberger, M. A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213–219 https://doi.org/10.1038/nrurol.2014.21 (2014).
Achard, V., Putora, P. M., Omlin, A., Zilli, T. & Fischer, S. Metastatic prostate cancer: treatment options. Oncology 100, 48–59 https://doi.org/10.1159/000519861 (2022).
Liao, R. S. et al. Emerging insights in small-cell carcinoma of the genitourinary tract: from diagnosis to novel therapeutic horizons. Am. Soc. Clin. Oncol. Educ. Book 44, e430336 https://doi.org/10.1200/EDBK_430336 (2024).
Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, eaav0891 https://doi.org/10.1126/scitranslmed.aav0891 (2019).
Aggarwal, R. et al. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin. Cancer Res. 31, 3854–3863 https://doi.org/10.1158/1078-0432.CCR-25-1211 (2025).
Chou, J. et al. Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer. Cancer Res. 83, 301–315 https://doi.org/10.1158/0008-5472.CAN-22-1433 (2023).
Dorff, T. et al. A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 30, 1488–1500 https://doi.org/10.1158/1078-0432.CCR-23-2978 (2024).
Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun. 15, 6779 https://doi.org/10.1038/s41467-024-51156-5 (2024).
Guo, C. et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur. Urol. 83, 224–238 https://doi.org/10.1016/j.eururo.2022.09.004 (2023).
Sperger, J. M. et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin. Cancer Res. 29, 2324–2335 https://doi.org/10.1158/1078-0432.CCR-22-1305 (2023).
Boixareu, C., Taha, T., Venkadakrishnan, V. B., de Bono, J. & Beltran, H. Targeting the tumour cell surface in advanced prostate cancer. Nat. Rev. Urol. 22, 569–589 https://doi.org/10.1038/s41585-025-01014-w (2025).
Davoudi, F. et al. Genomic and phenotypic biomarkers for precision medicine guidance in advanced prostate cancer. Curr. Treat. Options Oncol. 24, 1451–1471 https://doi.org/10.1007/s11864-023-01121-z (2023).
Choi, S. et al. Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocr. Relat. Cancer 33, e260268 https://doi.org/10.1530/ERC-26-0268 (2026).
Iwamoto, H. et al. Treatment outcomes in neuroendocrine prostate cancer. Anticancer Res. 42, 2167–2176 https://doi.org/10.21873/anticanres.15699 (2022).
Zhu, J. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine 100, e25237 https://doi.org/10.1097/MD.0000000000025237 (2021).
Catalano, M. et al. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Cancer Chemother. Pharmacol. 93, 1–9 https://doi.org/10.1007/s00280-023-04604-w (2024).
Hansel, D. E. & Epstein, J. I. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am. J. Surg. Pathol. 30, 1316–1321 https://doi.org/10.1097/01.pas.0000209838.92842.bf (2006).
Li, Y. et al. Beyond prostate adenocarcinoma: expanding the differential diagnosis in prostate pathologic conditions. Radiographics 36, 1055–1075 https://doi.org/10.1148/rg.2016150226 (2016).
Markowski, M. C., Eisenberger, M. A., Zahurak, M., Epstein, J. I. & Paller, C. J. Sarcomatoid carcinoma of the prostate: retrospective review of a case series from the Johns Hopkins Hospital. Urology 86, 539–543 https://doi.org/10.1016/j.urology.2015.06.011 (2015).
Humphrey, P. A. Histological variants of prostatic carcinoma and their significance. Histopathology 60, 59–74 https://doi.org/10.1111/j.1365-2559.2011.04039.x (2012).
Figueiredo, A. et al. Nonmetastatic castration-resistant prostate cancer: current challenges and trends. Clin. Drug Investig. 42, 631–642 https://doi.org/10.1007/s40261-022-01178-y (2022).
Tekin, B. et al. Sarcomatoid carcinoma of the prostate — a single institution experience with emphasis on molecular genetic findings. Hum. Pathol. 167, 105988 https://doi.org/10.1016/j.humpath.2025.105988 (2026).
Tan, H. L. et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890–903 https://doi.org/10.1158/1078-0432.CCR-13-1982 (2014).
Chehrazi-Raffle, A. et al. Unique spectrum of activating BRAF alterations in prostate cancer. Clin. Cancer Res. 29, 3948–3957 https://doi.org/10.1158/1078-0432.CCR-23-1393 (2023).
Wei, Y. et al. Analysis of three primary prostatic sarcoma cases and literature review. Prostate 84, 1218–1223 https://doi.org/10.1002/pros.24758 (2024).
De Bari, B. et al. Adult prostatic sarcoma: a contemporary multicenter Rare Cancer Network study. Prostate 77, 1160–1166 https://doi.org/10.1002/pros.23375 (2017).
Tward, J. D. et al. Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med. 7, 6030–6039 https://doi.org/10.1002/cam4.1872 (2018).
Zhao, J. et al. The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. Asian J. Surg. 46, 4178–4185 https://doi.org/10.1016/j.asjsur.2022.11.004 (2023).
Wang, J., Zhang, C., Chen, B. & Wu, Q. Basal cell carcinoma of the prostate with squamous metaplasia: a case report and literature review. Front. Oncol. 13, 1094943 https://doi.org/10.3389/fonc.2023.1094943 (2023).
Frankel, K. & Craig, J. R. Adenoid cystic carcinoma of the prostate. Report of a case. Am. J. Clin. Pathol. 62, 639–645 https://doi.org/10.1093/ajcp/62.5.639 (1974).
Komura, K. et al. Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinoma. Int. J. Clin. Oncol. 15, 594–600 https://doi.org/10.1007/s10147-010-0082-5 (2010).
Simper, N. B. et al. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum. Pathol. 46, 805–812 https://doi.org/10.1016/j.humpath.2015.02.004 (2015).
Ali, T. Z. & Epstein, J. I. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am. J. Surg. Pathol. 31, 697–705 https://doi.org/10.1097/01.pas.0000213395.42075.86 (2007).
Iczkowski, K. A. et al. Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am. J. Surg. Pathol. 27, 1523–1529 https://doi.org/10.1097/00000478-200312000-00004 (2003).
McKenney, J. K. et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am. J. Surg. Pathol. 28, 1289–1298 https://doi.org/10.1097/01.pas.0000138180.95581.e1 (2004).
Hasan, N. & Dodd, S. Basal cell carcinoma of the prostate. Histopathology 28, 571 https://doi.org/10.1046/j.1365-2559.1996.d01-477.x (1996).
Yang, X. J., McEntee, M. & Epstein, J. I. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum. Pathol. 29, 1447–1450 https://doi.org/10.1016/s0046-8177(98)90014-4 (1998).
Low, J. Y. et al. Genomic characterization of prostatic basal cell carcinoma. Am. J. Pathol. 193, 4–10 https://doi.org/10.1016/j.ajpath.2022.09.010 (2023).
Weier, C. et al. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J. Pathol. 230, 174–183 https://doi.org/10.1002/path.4186 (2013).
Magers, M. J. et al. MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod. Pathol. 32, 1666–1674 https://doi.org/10.1038/s41379-019-0297-6 (2019).
Chang, K. et al. Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature. World J. Surg. Oncol. 11, 193 https://doi.org/10.1186/1477-7819-11-193 (2013).
Funahashi, Y. Editorial comment to primary basal cell carcinoma of the prostate with concurrent adenocarcinoma. IJU Case Rep. 3, 61 https://doi.org/10.1002/iju5.12145 (2020).
Jiang, H. Tislelizumab: an effective anti-PD-1 antibody for the treatment of advanced basal cell carcinoma of the prostate. Urol. Case Rep. 57, 102742 https://doi.org/10.1016/j.eucr.2024.102742 (2024).
Rebhan, K., Wasinger, G., Hassler, M. R., Shariat, S. F. & Compérat, E. M. Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Curr. Opin. Urol. 32, 358–363 https://doi.org/10.1097/MOU.0000000000001007 (2022).
Su, W. et al. Definitive radiation therapy is a viable treatment for locally advanced basal cell carcinoma otherwise requiring radical or disfiguring resection. Int. J. Radiat. Oncol. Biol. Phys. 121, 677–683 https://doi.org/10.1016/j.ijrobp.2024.09.034 (2025).
Trinh, J. Q., Lele, S. M. & Teply, B. A. A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: systemic therapy for a rare disease. Prostate 83, 814–819 https://doi.org/10.1002/pros.24521 (2023).
Watanabe, R. et al. Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer. Urol. Oncol. 44, 110987 https://doi.org/10.1016/j.urolonc.2025.110987 (2026).
Farrugia, T. et al. ‘I knew I had to drive my own bus’: perspectives of patients and healthcare professionals on improving information provision to rare cancer survivors. J. Cancer Surviv. https://doi.org/10.1007/s11764-025-01896-0 (2025).
Marcus, D. M., Goodman, M., Jani, A. B., Osunkoya, A. O. & Rossi, P. J. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 15, 283–288 https://doi.org/10.1038/pcan.2012.4 (2012).
Gandaglia, G. et al. Prostate cancer registries: current status and future directions. Eur. Urol. 69, 998–1012 https://doi.org/10.1016/j.eururo.2015.05.046 (2016).
Mucci, L. A. et al. IRONMAN: a novel international registry of men with advanced prostate cancer. JCO Glob. Oncol. 8, e2200154 https://doi.org/10.1200/GO.22.00154 (2022).
Paller, C. J. et al. PROMISE Registry: a prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate 84, 292–302 https://doi.org/10.1002/pros.24650 (2024).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04923178 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03866382 (2026).
Zhu, L. et al. Case report: pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma. Front. Oncol. 14, 1382376 https://doi.org/10.3389/fonc.2024.1382376 (2024).
Hectors, S. J. et al. Radiomics features measured with multiparametric mMagnetic resonance imaging predict prostate cancer aggressiveness. J. Urol. 202, 498–505 https://doi.org/10.1097/JU.0000000000000272 (2019).
Hegde, N. et al. Similar image search for histopathology: SMILY. NPJ Digit. Med. 2, 56 https://doi.org/10.1038/s41746-019-0131-z (2019).
Subbiah, V., Othus, M., Palma, J., Cuglievan, B. & Kurzrock, R. Designing clinical trials for patients with rare cancers: connecting the zebras. Am. Soc. Clin. Oncol. Educ. Book 45, e100051 https://doi.org/10.1200/EDBK-25-100051 (2025).
Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49–58 https://doi.org/10.1038/s41591-022-02160-z (2023).
Miura, N. et al. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J. Urol. 204, 909–917 https://doi.org/10.1097/JU.0000000000001290 (2020).
Tan, Y. G. et al. Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: insight from over 1000 consecutive patients from a large prospective uro-oncology registry. Prostate 81, 242–251 https://doi.org/10.1002/pros.24100 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05053152 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05652686 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04388852 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04429087 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02861573 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04471727 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05760053 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05691465 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05413421 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT07111507 (2026).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06683846 (2025).
来源:Nature 健康护理主题 · nature.com